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Objective: In the past years, the canonical Wnt/b-catenin signaling pathway has emerged as a critical
regulator of cartilage development and homeostasis. In this pathway, glycogen synthase kinase-3b
(GSK3b) down-regulates transduction of the canonical Wnt signal by promoting degradation of b-cat-
enin. In this study we wanted to further investigate the role of Gsk3b in cartilage maintenance.
Design: Therefore, we have treated chondrocytes ex vivo and in vivowith GIN, a selective GSK3b inhibitor.
Results: InE17.5 fetalmousemetatarsals,GIN treatment resulted in loss of expressionof cartilagemarkers and
decreased chondrocyte proliferation fromday 1 onward. Late (3 days) effects of GIN included cartilagematrix
degradation and increased apoptosis. Prolonged (7 days) GIN treatment resulted in resorption of the meta-
tarsal. These changes were conﬁrmed by microarray analysis showing a decrease in expression of typical
chondrocytemarkers and induction of expression of proteinases involved in cartilagematrix degradation. An
intra-articular injection of GIN in rat knee joints induced nuclear accumulation of b-catenin in chondrocytes
72 h later. Three intra-articular GIN injectionswith a 2 days intervalwere associatedwith surface ﬁbrillation,
a decrease in glycosaminoglycan expression and chondrocyte hypocellularity 6 weeks later.
Conclusions: These results suggest that, by down-regulating b-catenin, Gsk3b preserves the chondrocytic
phenotype, and is involved in maintenance of the cartilage extracellular matrix. Short term b-catenin up-
regulation in cartilage secondary to Gsk3b inhibition may be sufﬁcient to induce osteoarthritis-like
features in vivo.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Differentiated chondrocytes maintain their phenotype via
synthesis of cartilage-speciﬁc extracellular matrix (ECM) molecules
including collagen type II and sulfated proteoglycans, like aggrecan1.
Chondrocytes easily lose essential characteristics when they are
removed from their natural environment and cultured in vitro or
expanded for the purpose of cartilage tissue engineering1,2.M. Karperien, Department of
ience & Technology, Institute
, Drienerlolaan 5, 7522 NB
0; Fax: 31-53-489-2150.
. Karperien).
n University Medical Centre,
s Research Society International. PChondrocyte dedifferentiation also occurs in the presence of retinoic
acid, nitric oxide, or proinﬂammatory cytokines like interleukin (IL)-1b
and Tumor necrosis factor (TNF)-a, as well as in osteoarthritis (OA)2.
We and others have shown that both constitutive up- or down-
regulation of the canonical Wnt pathway negatively inﬂuences
cartilage development and maintenance resulting in OA-like
features. This suggests that a tight regulation of this signaling
cascade is crucial throughout the chondrocyte life cycle3e6. In this
pathway, in the absence of a Wnt signal, a destruction complex
comprising Axin (Conductin) and Adenomatous polyposis coli (APC)
mediates the phosphorylation of b-catenin by glycogen synthase
kinase-3b (GSK3b), which induces degradation of cytosolic b-catenin
in the proteasome. Binding of Wnt to its transmembrane receptor
Frizzled results in activation of Dishevelled. This is followed by
reduction of GSK3b activity and accumulation of cytoplasmic
b-catenin. Upon its nuclear translocation, b-catenin will function asublished by Elsevier Ltd. All rights reserved.
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Wnt target genes6. GSK3b is constitutively active and, unlike many
kinases that are activated following stimulus-dependent phosphor-
ylation, it becomes inactive following phosphorylation7. Studies re-
ported so far indicate that Gsk3b activity is required for both
chondrocyte and osteoblast differentiation and thus for endochon-
dral bone development8. However, no data is available regarding the
role of GSK3b in maintenance of the chondrocytic phenotype.
To better understand the role of Gsk3b in regulation of the
chondrocyte life cycle,we inactivated this kinase ex vivo and invivoby
using 3-[9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]
diazepino[6,7,1-hi]indol-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-pyrrole-
2,5-dione, a selective and potent GSK3b inhibitor, in this manuscript
further referred to as GIN9. Our results imply that Gsk3b activity is
crucial for maintenance of the chondrocytic phenotype and for the
integrity of cartilage ECM, mainly by down-regulating the canonical
Wnt signaling pathway. The cartilage phenotypic changes induced by
GIN bear similarities to some of the clinical features commonly
observed in OA.
Materials and methods
KS483 cell culture, immunoﬂuorescence for b-catenin, transient
transfection assays
Routine culture of KS483 cells, immunoﬂuorescence for b-catenin
and transient transfection assays were performed as previously
described10.
Ex vivo experiments
The three middle metatarsals were dissected from E17.5 Swiss
Albino mouse embryos. Explants isolated from different animals
were randomly distributed and individually cultured in 500 ml
a-Minimum Essential Medium (MEM) (Invitrogen) medium con-
taining 10% Fetal Calf Serum (FCS) (Invitrogen), 100 U Pen/Strep
(Invitrogen) and 1% GlutaMax (Invitrogen). After an equilibration
period of 48 h, metatarsals were challenged with vehicle or GIN as
described in the results section. All ex vivo experiments were
approved by the ethical committee of the Leiden University
Medical Center and complied with national laws relating to the
conduct of animal experiments.
Proliferation and apoptosis assays
Chondrocyte proliferation was assessed by immunohistochem-
istry (IHC) for proliferating cell nuclear antigen (PCNA) according to
manufacturer’s protocol (Santa Cruz Biotechnology). Chondrocyte
apoptosis was determined by the Terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) reaction (Promega), as
previously described11. For statistical analysis a number of N¼ 3
independent samples were used and each experiment was repeated
at least once.
Histology, IHC, in situ hybridization (ISH)
Histology, IHC, and ISHwere performed as previously described5.
Quantiﬁcation of Glycosaminoglycans (GAGs)
The GAG content in N¼ 3 whole metatarsals per condition was
quantiﬁed related to the amount of DNA using the Blyscan Sulfated
GAG Assay kit (Biocolor) according to manufacturer’s protocol.
Experiments were repeated at least once.
Gene expression proﬁling
For each condition, RNA was isolated from N¼ 15 whole meta-
tarsals, checked for quality, ampliﬁed and labeled as previouslydescribed12. Labeled cRNAwas further used for the hybridization to
Affymetrix GeneChipMouse Genome 430A 2.0 Array according to
the manufacturer’s protocol. The raw and normalized data are
deposited on the website of the Department of Tissue Regeneration
of the Twente University Institute for Biomedical Technology
(http://tr.tnw.utwente.nl).
Microarray data analysis
To evaluate the large number of genes and to ﬁnd gene expres-
sion trends and noteworthy signaling pathways that are involved in
the GIN-mediated effects, we used principal component analysis13.
Using a cut-off value of 2 for the expression fold change, a list of 316
differentially expressed genes (225 down- and 91 up-regulated) was
generated and used for subsequent analysis (Tables SI and SII).
Functional annotation of the differentially expressed genes
identiﬁed by the principal component analysis (PCA) analysis was
performed using the DAVID bioinformatics database and the Gene
Ontology (GO) terms to describe their (extra)cellular location
(GO_CC), molecular functions (GO_MF), and the biological
processes (GO_BP) in which they are involved14e16. Enrichment of
GO functional groups was determined to be meaningful when the
number of probe sets in our list that mapped to a speciﬁc GO term
was greater than 2 with a P-value 0.001.
Validation of the microarray analysis was performed by real-
time quantitative polymerase chain reaction (PCR) as previously
described12.
In vivo experiments
All in vivo experiments were approved by the ethical committee of
the Erasmus University Medical Center and complied with national
laws relating to the conduct of animal experiments. Thirteen-week-old
maleWistar rats (400e450 g)were housed under standard laboratory
conditions (temperature 24C, 12-h lightedark cycle) with food and
water ad libitum. The animals were acclimatized to the laboratory
environment for 3 weeks before the start of the experiments.
GIN treatment
In a dose-ﬁnding study (N¼ 4), the effect of an intra-articular
injection of 100 ml GIN dissolved in phosphate buffered saline (PBS)
at concentrations of 3107 M, 106 M, 3106 M, and 105 M in
the knee joint was investigated.
In a second experiment, eight rats were injected intra-articularly
at day 1, 3 and 5with 100 ml 105 MGIN. Four ratswere injectedwith
GIN in the left knee, the remaining four were injected in the right
knee. Contralateral joints served as controls and were injected with
vehicle. All animals were scanned using contrast-enhanced microCT
(CECT) beforeGIN injection (t¼ 0) andduring followupas previously
described17. Rats were sacriﬁced at the times indicated in the text.
Microscopical analysis and quantiﬁcation
IHC for b-catenin coupled with Alcian Blue (AB) counterstaining
for GAGs was carried out as previously described5. Quantiﬁcation of
the AB staining was performed using Image-Pro Plus software,
version 7.0.
Statistical analysis
All values represent median and range for experiments when
N 4 and mean and 95% conﬁdence interval (CI) when N 5. The
paired t-test, the univariate general linear model using simple
contrasts and parameter estimates and one-way analysis of variance
(ANOVA) were used to assess the data, as appropriate. P values less
than 0.05 were considered signiﬁcant. Statistical analysis was per-
formed using SPSS v16.0 (SPSS).
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Inhibition of Gsk3b through GIN results in activation of the
canonical Wnt signaling pathway in vitro and ex vivo
We ﬁrst performed transient transfection experiments in
mesenchymal-like KS483 cells using the Wnt-responsive BAT-Luc
reporter vector10,18. As expected, GIN induced a dose-dependent
increase in luciferase activity, with a maximum response at 107 M
[Fig.1(A)]. At higher concentrations, the luciferase activity decreased,
presumably due to toxic effects [Fig. 1(A) and data not shown].
Furthermore, GIN was signiﬁcantly more potent in inducing theWnt
reporter construct than LiCl, another established inhibitor of GSK3b.
Activation of the Wnt reporter construct by 107 M GIN was
accompanied by b-catenin accumulation and nuclear translocation
as conﬁrmed by immunoﬂuorescence [Fig. 1(B)]. The overall level of
b-catenin was notably increased in cells treated with GIN when
compared to LiCl (50 mM) or Wnt3a (50 ng/ml) [Fig. 1(B)].
We next investigated the effect of GIN on fetalmousemetatarsals,
which represent an established model for studying the chondrocyte
life cycle ex vivo19. After incubation for 3 days, GIN dose-dependently
increased the levels of b-catenin as revealed by IHC [Fig. 1(C)].
Metatarsals treated with either 107 M or 106 M GIN displayed
b-catenin staining mainly in the nuclei, indicating an efﬁcient acti-
vation of the canonical Wnt signal. The latter concentration resulted
in immunohistochemically detectable nuclear b-catenin expression
in almost all chondrocytes. Strikingly, metatarsals treated with
106 M GIN displayed a much fainter AB counterstaining in
comparison to controls, indicative for loss of GAGs. Additional
morphological analysis revealed no evidence of cell death, cellFig. 1. GIN activates the canonical Wnt signaling pathway via b-catenin. (A) GIN activated a
represent the mean and 95% CI (error bars) of N¼ 9 luciferase observations corrected for
(50 mM) and Wnt3A (50 ng/ml) on b-catenin localization in KS483 cells as revealed by imm
and inducing nuclear translocation of b-catenin. Scale bar¼ 10 mm. (C) Representative imag
murine metatarsals treated for 3 days with the indicated concentrations of GIN. In this expe
without any sign of toxicity. Note the progressive decrease in the intensity of the AB staining
Scale bars¼ 100 mm (upper row), 25 mm (lower row).shrinkage, picnotic nuclei, blebbing of the cytoplasm or necrosis.
Subsequent experiments using the fetal mouse metatarsal ex vivo
culture model were performed with 106 M GIN.
GIN inhibits chondrocyte proliferation and increases
cartilage apoptosis
We assessed the effect of GIN on chondrocyte proliferation using
IHC for PCNA. The percentage of proliferating cells was smaller in
the GIN-treated group compared to controls at all time points
examined [Fig. 2(AeE)]. Chondrocyte proliferationwas signiﬁcantly
inhibited both at d1 (11.3% vs 25.9%, P¼ 0.048) and at d3 (7.6% vs
27.8%, P¼ 0.014). TUNEL staining in combination with histological
evaluation was used to assess chondrocyte apoptosis. GIN did not
have an effect onTUNEL positivity at 6h, d1 andd3 [Fig. 2(FeJ)]. Only
after prolonged GIN treatment (d7), TUNEL staining was signiﬁ-
cantly increased (22.9% vs 6.0%, P¼ 0.043). At d7, TUNEL-positive
cells were predominantly identiﬁed among the hypertrophic
chondrocytes in controls. In contrast, TUNEL-positive cellswere also
observed among the resting and proliferative chondrocytes in the
GIN-treated group. Based on histological evaluation, TUNEL-
positive cells underwent apoptosis.
Inhibition of Gsk3b induces degradation of cartilage matrix and loss
of the chondrocytic phenotype ex vivo
We investigated the effect of GIN at the cellular level by IHC
analysis for b-catenin, collagen type II and X, and ISH analysis for
Col2a1 and Col10a1. No microscopical differences between vehicle-
and GIN-treated metatarsals were observed at 6 h (data nottransiently transfected Wnt reporter construct in KS483 cells dose-dependently. Values
renilla luciferase. (B) Representative images showing the effect of GIN (107 M), LiCl
unoﬂuorescence. Out of the three Wnt activators, GIN was most effective in stabilizing
es showing b-catenin IHC combined with AB staining on longitudinal sections of E17.5
rimental set-up, 106 M GIN induces nuclear b-catenin translocation in almost all cells
. The boxed regions in the upper row pictures are magniﬁed in the lower row pictures.
Fig. 2. GIN inhibits chondrocyte proliferation and augments cartilage apoptosis. (AeD) Representative images showing PCNA IHC on metatarsals treated with vehicle (A, C) or GIN
(B, D) for 1 day. Note that the number of the PCNA-positive nuclei (brown) is decreased in the GIN-treated metatarsal. (E) Quantiﬁcation in N¼ 3 independent samples of the PCNA-
positive nuclei (examples indicated by black arrows in C, D) indicates signiﬁcant inhibition of chondrocyte proliferation upon GIN treatment at d1 and d3. PCNA-positive cells were
counted on a mid sagital tissue section. Each ﬁeld contained at least 500 cells and data are expressed as median (range) % of PCNA-positive cells from total number of cells. (FeI)
Representatives pictures of metatarsals cultured in control (F, H) or GIN-enriched (G, I) medium for 7 days after TUNEL staining. Note that the number of the TUNEL-positive nuclei
(brown) is increased in the GIN-treated metatarsal. (J) Quantiﬁcation in N¼ 3 independent samples of the TUNEL-positive nuclei (examples indicated by black arrows in H, I)
indicates signiﬁcantly more chondrocyte apoptosis upon prolonged GIN treatment (d7). Quantiﬁcation and data expression as in (E). (C, D, H, I) High magniﬁcation pictures of the
boxed regions in A, B, F, and G, respectively. Scale bars: 100 mm (A, B, F, G), 25 mm (C, D, H, I).
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the control metatarsals at d1, d3 and d7 was restricted to the
cytoplasm of a minority of perichondrial and periosteal cells
[Fig. 3(A, Ai, Aiii, Av)]. We ﬁrst noticed a clear increase in the level of
nuclear b-catenin after 1 day of GIN treatment [Fig. 3(Aii)].
b-catenin accumulation was observed at d3 and d7 as well
[Fig. 3(Aiv, Avi)]. The level of nuclear b-catenin was inversely
correlated with the intensity of the AB counterstaining
[Fig. 3(AeAvi)]. GIN treatment progressively decreased the GAG
content in the ECM, with a near complete loss of GAGs at d7
[Fig. 3(F)]. GIN did not have an effect on mineral deposition and
ossiﬁcation of the metatarsals (data not shown).
Additional microscopical analysis revealed Col2a1 mRNA and
collagen type II protein expression in the resting, proliferative and
prehypertrophic chondrocytes, and their matrix, respectively, at all
time points in the controls [Fig. 3(B, Bi, Biii, Bv, C, Ci, Ciii, Cv)]. GIN
treatment for 1 day resulted in a considerable inhibition of the
mRNA expression of this chondrocyte marker, whereas its protein
expression was not changed [Fig. 3(Bii, Cii)]. At d3, most of the
chondrocytes in the GIN-treated metatarsals, although surrounded
by a matrix rich in collagen type II, failed to express Col2a1
[Fig. 3(Biv, Civ)]. At d7, neither Col2a1 nor collagen type II expression
was found in the GIN-treated metatarsals [Fig. 3(Bvi, Cvi)].
Furthermore, control metatarsals displayed Col10a1 and
collagen type X expression in the hypertrophic zone [Fig. 3(D, Di,
Diii, Dv, E, Ei, Eiii, Ev)]. At d1, there were no differences in the
expression of this mature chondrocyte marker between the control
and the GIN-treated group, neither at the mRNA nor at the protein
level [Fig. 3(Dii, Eii)]. At d3, GIN-treated explants displayed no
Col10a1 expression, whereas collagen type Xwas still present in the
ECM [Fig. 3(Div, Eiv)]. Ultimately, at d7, GIN induced a complete
absence of both Col10a1 and collagen type X [Fig. 3(Dvi, Evi)].Microarray analysis conﬁrms GIN’s proteolytic effects on cartilage
To further examine the effects of GIN on gene expression patterns
in the fetal mouse metatarsal model, we performed cDNA micro-
array analysis on mRNA isolated from GIN-treated and control
explants at T0, 6h, d1 and d3. We particularly designed our micro-
array analysis as such since GIN-treated metatarsals at d7 showed
only aggravated features of the ones observed at d3. Furthermore,
the increased apoptosis at d7 would have jeopardized the speciﬁcity
of the results and mainly revealed differentially expressed genes
related to cell death, an indirect effect of GIN treatment.
According to GO_CC terms, the vast majority of the 316 differ-
entially expressed genes (225 down- and 91 up-regulated) encoded
proteins that are active in the ECM [Fig. 4(A)]. Classiﬁcation
according to GO_MF and GO_BP terms is represented in Fig. 4(B and
C), respectively. The large number of up-regulated genes and the
fact that they did not categorize under any GO terms related to cell
death suggested that our microarray data efﬁciently revealed bio-
logical effects caused by GIN treatment and not by toxicity.
In consistence with the microscopical ﬁndings indicating signiﬁ-
cant cartilage matrix degradation, we found among the 91 up-
regulated genes numerous transcripts encoding established
proteinases:Matrixmetallopeptidase 9 (Mmp9),Mmp10,Mmp11, and
HtrA serine peptidase 1 (Htra1). Given the role of GSK3b in canonical
Wnt signaling, the microarray data showed evidence for a Wnt/b-
catenin signature as evidenced by the up-regulation of established
direct targets of the b-catenin/TCF4 complex, like Axin2 and adeno-
matosis polyposis coli down-regulated 1 (Apcdd1). Microarray and
pathway analysis did not reveal clear signatures of changes in other
signaling pathways, such as Hedgehog (Hh) and Fibroblast growth
factor (FGF). Furthermore, several cartilage ECM proteins were
identiﬁed among the 225 down-regulated genes: unique cartilage
Fig. 3. GIN induces loss of the chondrocytic phenotype ex vivo. Representativepictures of (AeAvi) b-catenin immunostaining combinedwith AB staining, (BeBvi)Col2a1mRNAexpression,
(CeCvi) Collagen type II immunostaining, (DeDvi)Col10a1mRNAexpression, and (EeEvi) Collagen typeX immunostaining, on consecutive longitudinal sections of E17.5mousemetatarsals
(N¼ 3 independent samples) isolated at the indicated time points. b-catenin-positive chondrocytes lose Col2a1 expression upon GIN treatment already at d1. Chondrocyte marker
expression at themRNA level is inhibited after 3-day-longGIN treatment. Chondrocytes exposed toGIN for 7 days fail to express speciﬁcmarkers at bothmRNAandprotein level. Scale bar:
100 mm. (F) Quantiﬁcation of GAGs corrected for DNA (N¼ 3 independent samples) validates themicroscopical ﬁndings. *P¼ 0.023 (d1), *P¼ 0.016 (d3), **P¼ 0.008 (d7), all GIN vs same
time point untreated. Data are expressed in arbitrary GAG/DNA units (black triangles e controls, gray triangles e GIN-treated samples).
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hyaluronan and proteoglycan link protein 1 (Hapln1), collagen, type
XI, alpha 1 (Col11a1), epiphycan (Epyc), ﬁbromodulin (Fmod), matrix
Gla protein (Mgp),Col14a1, and (Col9a3). In the list of repressed genes,
we also found transcripts known to encode non-cartilaginous matrix
proteins like osteomodulin (Omd), osteoglycin (Ogn), microﬁbrillar-associated protein 4 (Mfap4), tenomodulin (Tnmd), asporin (Aspn),
and ﬁbulin7 (Fbln7), suggesting a more complex effect of the GIN
treatment on the ECM.
To independently validate the results of the microarray analysis,
16 genes were selected for conﬁrmation by quantitative real-time
RT-PCR analysis. For the transcriptional analysis we therefore
Fig. 4. Functional annotation of the GIN-modulated genes according to GO terms. Functional annotation according to GO_CC (A), GO_MF (B) and GO_BP (C) terms was used to
determine the enrichment of the differentially expressed transcripts indicated by PC1.
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to generate themicroarray data. Four of these 16 genes are known to
be involved in chondrocyte differentiation and cartilage mainte-
nance (Sox9, Col2a1, Acan and Col10a1), four are members of the
canonical Wnt signaling pathway (Axin1, Axin2, Gsk3b and Ctnnb1),
and eight encode proteinases known to regulate maintenance and
degradation of the ECM (Mmp2, Mmp3, Mmp9, Mmp13, Adamts4,
Adamts5, Hyal1 and CtsK). We found a similar expression pattern of
the analyzed genes, indicating that our microarray data speciﬁcally
corresponded to actual gene expression patterns (Fig. 5).
GIN induces OA-like effects in vivo
Wenext investigatedwhether GIN can induce the same biological
effects in an in vivo experimental model. In an initial experiment, we
observed 72 h after GIN injection nuclear translocation of b-catenin
in a dose-dependent fashion in rat knee articular chondrocytes,
whereas vehicle treatment did not induce a change in b-catenin
expression in the control joints [Fig. 6(A, Ai, B, Bi and data not
shown)]. Virtually all articular chondrocytes treatedwith the highest
GIN concentration (105 M) showed nuclear b-catenin expression,
yet they did not display any morphological changes or alterations of
their ECM.We did not detect b-catenin up-regulation in other tissues
such as synovium, tendons, or bone at the examined time point, nor
evidence of inﬂammation.
In a second experiment, we injected 105 MGIN on day 1, 3 and 5.
Four rats (“early”group)displayed signs of severe acute inﬂammation
of the GIN-treated knee beginning at day 7 and these animals were
therefore sacriﬁced already at day 10. No difference in b-catenin
expressionwas observed between the GIN-treated and control knees
of these animals (data not shown). In the vehicle-injected knee, thesurface of the articular cartilage (AC) was smooth, the matrix was
densely stained with AB and showed no signs of degeneration
[Fig. 6(C, Ci)]. Besides displaying histological signs of inﬂammation
(intra-articular inﬁltration of neutrophils and macrophages, syno-
viocyte hyperplasia, ﬁbrin exudation etc.), the GIN-treated knees in
the “early” groupdisplayed intensely degradedAC, containing almost
no GAGs, as indicated by absence of AB staining [Fig. 6(D, Di and data
not shown)] in each of the four animals.
The other four rats (“late“ group) from this experiment were
sacriﬁced after 6 weeks and again showed no difference in the
b-catenin expression pattern between the GIN-treated knee and
controls [Fig. 6(E, Ei, F, Fi)]. Whereas no morphological changes were
observed in the control knees of the “late“ group, GIN-treated
samples from all four rats displayed superﬁcial ﬁbrillation of AC,
focal hypocellularity of chondrocytes, and reduced AB staining.
Quantiﬁcation of the intensity of the AB staining revealed signiﬁ-
cantly less staining in the cartilage of GIN-treated knees in
comparison to contralateral control knees [Fig. 6(G), P¼ 0.05].
Although not statistically signiﬁcant, CECT analysis of condylar
cartilage revealed a trend in reduction of cartilage volume aswell as
GAG-depletion (expressed by increased attenuation) in the
GIN-treated knee joints in comparison to control knees [Fig. 6(H, I)].
Discussion
Here we show that Gsk3b, by controlling the canonical Wnt
signaling pathway, is critical for maintenance of the chondrocytic
phenotype. InhibitionofGsk3b in chondrocytes ex vivo leads to loss of
cartilage markers expression, induces matrix degradation by stimu-
lating the expression of Mmps, inhibits chondrocyte proliferation
and, most likely as a consequence of these effects, induces
Fig. 5. Quantitative Real-Time RT-PCR validates themicroarray data. Correlation between qPCR andmicroarray results for Sox9, Col2a1, Acan, Col10a1, Axin1, Axin2, Gsk3b, Ctnnb1,Mmp2,
Mmp3, Mmp9, Mmp13, Adamts4, Adamts5, Hyal1, and CtsK. The primary y-axis (left) indicates the RT-PCR results as normalized fold change on a log-scale. The secondary y-axis (right)
indicates the microarray results as the log-differential expression ratios (M). Data are expressed as the mean of N¼ 6 metatarsals (qPCR) and N¼ 15 metatarsals (microarray).
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inhibition of Gsk3b, following three intra-articular injections of GIN
in rat knees during 1 week is associated with the appearance of OA-
like features 6 weeks later. In agreement with our results, recent
ﬁndings suggest that up-regulation of b-catenin through induction of
proteasomal degradation of Gsk3b in chondrocytes initiates
early events of OA, while inhibition of Gsk3b may block
chondrogenesis20,21.
Besides the canonical Wnt pathway, GSK3b also regulates signal
transduction of the Hh and Fibroblast growth factor (Fgf) family of
secreted proteins22,23. Given that both Hh and Fgf growth factors
play important roles in the chondrocyte life cycle, we searched in
our microarray results for possible target genes of these proteins
among the list of transcripts differentially regulated by GIN24,25.
Only PR domain containing 1, with zinc ﬁnger (ZNF) domain
(Prdm1) matched this criterion, acting downstream of a sequential
Wnt and Fgf signaling cascade26. Our microarray expression data
indicated that GIN treatment up-regulated the canonical Wnt
target genes Axin2 and Apcdd1, transcripts that have previously
been shown to be induced only by Wnt and not by Fgf signal-
ing27e29. The protein products of Axin2 and Naked cuticle homolog 2,
both of which are up-regulated in the microarray, are both
renowned antagonists of the canonical Wnt signal. They have been
shown to participate in negative feedback regulation of b-cateninactivity30e32. Taken together, these ﬁndings suggest that the
intense cartilage matrix degeneration as well as the loss of the
chondrocytic phenotype following GIN treatment occurred, at least
in our experimental set-up, mainly due and can be explained by the
activation of the Wnt/b-catenin pathway, although we cannot
exclude minor roles of other signaling pathways in which GSK3b is
known to be implicated nor of minor off-target effects of GIN.
Previously,we andothershave reported that continuousexposure
of chondrocytes to extensive levels of b-catenin in vivo induces loss of
the chondrocytic phenotype as evidenced by the loss in expression of
typical chondrocyte markers5,6. Microarray analysis of GIN-treated
metatarsals conﬁrmed and extended this observation. Furthermore,
our microscopical analysis suggests that GIN not only induced an
enhanced degradation of the ECM, but also inhibited the expression
of several ECM constituents in a time-dependent manner. Note-
worthy, in the metatarsal experiments the loss of expression of
typical cartilage markers at the mRNA level was observed before
protein degradation was noticeable. GIN treatment inhibited the
expression of genes encoding collagenous (Col9a3, Col11a1, and
Col14a1), and non-collagenous ECM proteins (Ucma, Matn1, Matn3,
Matn4, Hapln1, Fmod, Mgp), as well as proteoglycans (Epyc).
In addition, GIN stimulated the expression of proteinases Mmp9,
Mmp10, Mmp11, and Htra1, which promote ECM degradation, sug-
gesting that the loss of tissue integrity observed in the treated
Fig. 6. GIN induces OA-like effects in rat articular cartilage. (A, B) Representative pictures of b-catenin IHC combined with AB staining on longitudinal mid sagital sections of tibial
plateaus 72 h after injection with vehicle (A) or 105 M GIN (B). Seventy-two hours after GIN injection there is b-catenin up-regulation (arrows in Bi). (C, D) Representative pictures
of AB staining on longitudinal mid-sagital sections of proximal tibias 10 days after injection with vehicle (C) or 105 M GIN (D) indicate massive ECM degradation only in the
GIN-treated articular cartilage (arrowheads). GP cartilage is unaffected in both conditions (arrows). (E, F) Representative pictures of b-catenin IHC combined with AB staining on
longitudinal mid-sagital sections of tibial plateaus 6 weeks after injection with vehicle (E) or 105 M GIN (F). Short term GIN treatment does not lead to b-catenin up-regulation
6 weeks later, but induces OA-like morphological changes of the articular cartilage. (Ai, Bi, Ci, Di, Ei, Fi) High magniﬁcation pictures of the boxed regions in A, B, C, D, E and F,
respectively. (G) Quantiﬁcation of the intensity of the AB staining, at 6 weeks, in the control and GIN-treated knees (N¼ 4 independent samples) showing less GAGs in the treated
samples. Data are expressed as median (range) AB arbitrary units, P¼ 0.050. (H, I) Quantiﬁcation of volume and attenuation measurements from CECT-data (N¼ 4 independent
samples) (black triangles e controls, gray triangles e GIN-treated samples). Scale bars: 200 mm (A, B, Ci, Di, E, F), 20 mm (Ai, Bi, Ei, Fi), 300 mm (C, D).
R.L. Miclea et al. / Osteoarthritis and Cartilage 19 (2011) 1363e13721370metatarsals is due not only to a loss of the links between the
collagenous and the non-collagenous proteins in the matrix, but also
to active matrix degradation.
Decreased chondrocyte proliferation, augmented apoptosis, loss
of the chondrocytic phenotype and degradation of ECM together
characterize the “degradative phase” of OA, the most common form
of arthritis33. These pathological phenomena were observed after
up-regulated canonical Wnt signaling by GIN treatment in our
experimental set-ups ex vivo and in vivo, in agreement with
recent data suggesting a link between excess signaling through the
Wnt/b-catenin pathway and OA6. Moreover, many genes reportedly
induced in OA cartilage were up-regulated by GIN treatment:
Mmp9, Mmp10, Mmp11, Axin2, Htra1, angiopoietin-like 2 (Angptl2),
and met proto-oncogene (Met)2,34e38. Htra1, which is increased
several-fold in joint cartilage of OA patients, promotes degenera-
tion of cartilage36,39, while Met, besides contributing to the altered
metabolism during OA, also stimulates osteophyte development40.
Serping1, previously reported to be repressed in OA, and Matn3,
whose inactivation leads to higher incidence of OA, were bothdown-regulated by GIN41,42. In addition, inactivation of Frzb,
another transcript repressed by GIN treatment, renders joints more
susceptible for osteoarthritic changes43.
Our results suggest that treatment with GIN can induce cartilage
degeneration of rat AC after three intra-articular injections of GIN
with 2 days interval. We observed two distinct phenotypes, most
likely explained by a difference in retention time of GIN in the knee
joint: a severe form with acute inﬂammation associated with
resorption already 10 days after the ﬁrst injection a milder pheno-
type. The potent catabolic effects of GIN on cartilagemay have caused
rapid and excessive cartilage degradation. These degradation prod-
ucts may have triggered an acute form of inﬂammation through the
release of for example collagen type II fragments. In animals with the
milder phenotype, microscopical analysis demonstrated the pres-
ence of the ﬁrst signs of OA-like changes such as surface ﬁbrillation,
focal chondrocyte hypocellularity and a decrease in GAG staining in
GIN-treated knees but not in the contralateral control knees 6 weeks
after the last GIN injection. CECT analysis revealed a trend of less
cartilage volume andmore attenuation, indicative for GAG loss in the
R.L. Miclea et al. / Osteoarthritis and Cartilage 19 (2011) 1363e1372 1371GIN-treated animals; however this observation did not reach signif-
icance. In contrast to the increasedb-cateninexpression inACpresent
3 days after GIN injection, we did not detect increased b-catenin
staining 6 weeks after GIN injection nor did we found evidence for
nuclear b-catenin accumulation in the synovium, tendons or bone at
each of the analyzed time points. This suggests that a transient rise in
b-catenin in AC may be sufﬁcient to trigger development of OA-like
features, an observation that extends ﬁndings in conditional consti-
tutive mice carrying a stabilized, oncogenic variant of b-catenin,
which also develop OA4. Although we did not ﬁnd evidence for
increased b-catenin accumulation in other joint tissues besides
cartilage at the examined time points, we cannot exclude that GIN
injection has resulted in a more rapid and transient rise of b-catenin
in these tissues which was normalized 72 h after the injection. This
may have also contributed to the observed pathology. Furthermore,
we cannot exclude that the mild cartilage phenotype was due to
a milder form of inﬂammation in the ﬁrst weeks after injection.
However, given the clear evidence of increased nuclear b-catenin
accumulation inAC72 hafterGIN injection and the consistencyof the
in vivo ﬁndings with the phenotypic changes and effects on gene
expression of GIN in our ex vivo cartilage explantmodel, we favor the
hypothesis that these ﬁrst indications of cartilage degenerationwere
due to a transient rise in b-catenin in AC triggering cartilage catab-
olism and changes in the chondrocyte phenotype.
Abnormally regulated GSK3b has been associated with many
pathological conditions like Alzheimer’s disease, mood disorders,
diabetes and cancer7. However, a direct link between GSK3b and
the pathophysiology of OA has not yet been reported. Since in our
experimental set-ups the GIN-induced effects reﬂect some of the
pathological ﬁndings normally seen in osteoarthritic chon-
drocytes, we speculate that Gsk3b plays a role in the pathophys-
iology of this degenerative cartilage disease as well, most likely by
regulating the levels of b-catenin. Whether pharmacological
modulation of Gsk3b might represent a potential novel ther-
apeutical approach for the management of OA remains to be
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